



Developing biosimilar mAbs in breast cancer: what are the critical components for clinical confidence?

Sunday 9 October 2016, 18.30–20.00

Oslo Auditorium, Bella Center, Copenhagen, Denmark

Programme

Chair: Michael Gnant, Austria

Welcome and introduction

Michael Gnant, Austria

Biosimilars: unlocking access to affordable cancer care?

Paul Cornes, UK

Biosimilar mAbs in HER2+ breast cancer

The complex interplay between structure and function

Joan Albanell, Spain

Defining sensitive patient populations and sensitive endpoints for biosimilar clinical trial designs

Sara Hurvitz, USA

Closing comments

Michael Gnant, Austria